Literature DB >> 17343315

Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis.

Edward M Behrens1, Timothy Beukelman, Michele Paessler, Randy Q Cron.   

Abstract

OBJECTIVE: Macrophage activation syndrome (MAS) is a well described, but purportedly uncommon manifestation of systemic juvenile idiopathic arthritis (SJIA). There is evidence to suggest that macrophage activation is integral to the pathogenesis of SJIA. Accordingly, many patients with SJIA may have evidence of mild MAS that is not appreciated clinically. We investigated the prevalence of occult MAS in children with SJIA by reviewing bone marrow aspirates (BMA).
METHODS: Patients diagnosed with SJIA who underwent bone marrow aspiration were identified retrospectively. Patients admitted with a diagnosis of fever of unknown origin and discharged with a diagnosis other than SJIA or malignancy, and who had a BMA, were identified as controls. The BMA were reviewed by a single hematopathologist for evidence of MAS, ranging from activated macrophages to frank hemophagocytic cells.
RESULTS: Eight of 15 (53%) patients with SJIA had BMA suggestive of MAS. Two of 15 patients (13%) were diagnosed clinically with MAS. Three patients (20%) were noted to have frank hemophagocytosis, only one of whom was diagnosed with MAS clinically. There were no statistically significant differences in the laboratory values for the patients with and without evidence of MAS on BMA. There was no evidence of increased macrophage activity or hemophagocytosis in any of the control BMA.
CONCLUSION: Occult MAS appears to be common in patients with SJIA who undergo BMA. This suggests that macrophage activation may be integral to the pathogenesis of SJIA, with implications for treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17343315

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  119 in total

1.  Functional and genetic testing in adults with HLH reveals an inflammatory profile rather than a cytotoxicity defect.

Authors:  Julien Carvelli; Christelle Piperoglou; Catherine Farnarier; Frédéric Vely; Karin Mazodier; Sandra Audonnet; Patrick Nitschke; Christine Bole-Feysot; Mohamed Boucekine; Audrey Cambon; Mohamed Hamidou; Jean-Robert Harle; Geneviève de Saint Basile; Gilles Kaplanski
Journal:  Blood       Date:  2020-07-30       Impact factor: 22.113

2.  Alternative activation in systemic juvenile idiopathic arthritis monocytes.

Authors:  Claudia Macaubas; Khoa D Nguyen; Ariana Peck; Julia Buckingham; Chetan Deshpande; Elizabeth Wong; Heather C Alexander; Sheng-Yung Chang; Ann Begovich; Yue Sun; Jane L Park; Kuang-Hung Pan; Richard Lin; Chih-Jian Lih; Erin M Augustine; Carolyn Phillips; Andreas V Hadjinicolaou; Tzielan Lee; Elizabeth D Mellins
Journal:  Clin Immunol       Date:  2011-12-28       Impact factor: 3.969

3.  Hypocomplementemia associated with macrophage activation syndrome in systemic juvenile idiopathic arthritis and adult onset still's disease: 3 cases.

Authors:  Mark Gorelik; Kathryn S Torok; Daniel A Kietz; Raphael Hirsch
Journal:  J Rheumatol       Date:  2011-02       Impact factor: 4.666

4.  Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China.

Authors:  Li-Xia Zou; Yun Zhu; Li Sun; Hui-Hui Ma; Si-Rui Yang; Hua-Song Zeng; Ji-Hong Xiao; Hai-Guo Yu; Li Guo; Yi-Ping Xu; Mei-Ping Lu
Journal:  World J Pediatr       Date:  2019-10-14       Impact factor: 2.764

Review 5.  Macrophage activation syndrome complicating rheumatic diseases in adults: case-based review.

Authors:  Mayan Gilboa; Gil Bornstein; Ilan Ben-Zvi; Chagai Grossman
Journal:  Rheumatol Int       Date:  2019-07-31       Impact factor: 2.631

6.  Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states.

Authors:  Claudia Macaubas; Khoa Nguyen; Chetan Deshpande; Carolyn Phillips; Ariana Peck; Tzielan Lee; Jane L Park; Christy Sandborg; Elizabeth D Mellins
Journal:  Clin Immunol       Date:  2009-10-29       Impact factor: 3.969

Review 7.  The genetics of macrophage activation syndrome.

Authors:  Grant S Schulert; Randy Q Cron
Journal:  Genes Immun       Date:  2020-04-15       Impact factor: 2.676

8.  A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment.

Authors:  Mark Wunderlich; Courtney Stockman; Mahima Devarajan; Navin Ravishankar; Christina Sexton; Ashish R Kumar; Benjamin Mizukawa; James C Mulloy
Journal:  JCI Insight       Date:  2016-09-22

9.  2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.

Authors:  Sarah Ringold; Pamela F Weiss; Timothy Beukelman; Esi Morgan DeWitt; Norman T Ilowite; Yukiko Kimura; Ronald M Laxer; Daniel J Lovell; Peter A Nigrovic; Angela Byun Robinson; Richard K Vehe
Journal:  Arthritis Rheum       Date:  2013-10

10.  Performances of the "MS-score" And "HScore" in the diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis patients.

Authors:  Erdal Sag; Armagan Keskin; Erdal Atalay; Selcan Demir; Muserref Kasap Cuceoglu; Ummusen Kaya Akca; Ezgi Deniz Batu; Yelda Bilginer; Seza Ozen
Journal:  Rheumatol Int       Date:  2020-11-19       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.